PCSK9 and acute coronary syndrome: Given the recently accumulated data in acute coronary syndromes (ACS), this review aims to analyze post-ACS lipid-lowering rationale and delve into the early utilization of PCSK9 inhibitors in high-risk patients, highlighting the simultaneous importance of “the lower-the better” and “the sooner-the better” guide toward decreasing cardiovascular mortality [15].